Mechanisms of Vascular Dysfunction in Diabetes Mellitus Lynette Pittman, RN, Nurse Clinician, Heart Health Services, Calgary Health Region
|
|
- Darcy Jones
- 5 years ago
- Views:
Transcription
1 Mechanisms of Vascular Dysfunction in Diabetes Mellitus Lynette Pittman, RN, Nurse Clinician, Heart Health Services, Calgary Health Region By 2020 cardiovascular disease (CVD) will dominate all other causes of deaths and surpass infectious disease as the world s greatest killer. 1 According to the World Health Organization models, by 2025 the number of persons with diabetes will expand by 35 percent worldwide. 1 What will be our role as health care professionals as we endeavor to deal with the combined impact of cardiovascular disease and diabetes? No matter what our specialty we will be touched, if not through our patients, through our families and friends. We must begin with a thorough knowledge and understanding of the adversaries, diabetes and cardiovascular disease. Although less well understood than our evolving understanding of the pathogenesis of atherosclerosis itself, novel risk factors for the accelerated development of atherosclerosis in the presence of diabetes have been identified. 2 This paper will focus on those mechanisms of diabetes that may predispose a hastening of the atherosclerotic process. Diabetes Mellitus and Cardiovascular Disease Risk As it relates to cardiovascular risk, notable differences exist between the two types of diabetes, with type II diabetic individuals developing CVD at a younger age, having a higher rate of multi-vessel disease and poorer outcomes post myocardial infarction than their type I counterparts. 2 The Multiple Risk Factor Intervention Trial(MR.FIT) found diabetic men with one, two or three CVD risk factors experienced higher disease mortality than nondiabetic individuals with the same number of risk factors. Diabetes played an additive role when combined with one or more risk factors. 3 The United Kingdom Prospective Study (UKPDS) following newly detected diabetic individuals, found increased risk of CVD was significantly associated with risk factors of increased LDL, decreased HDL increased HGB A1c, elevated systolic blood pressure and smoking when measured at baseline. 4 Despite the undeniable association of established CVD risk factors and diabetes, these risk factors account for only 50 per cent of the excess CVD in the diabetic. 2,5 Hyperglycemia, hyperinsulinemia and insulin resistance, dyslipidemia, increased plasma oxidative stress, enhanced fibrinolysis and abnormal vasodilator function are some of the proposed mechanisms and novel risk factors for the accelerated development of atherosclerosis and diabetes. 2 Mechanisms of Vascular Dysfunction in Diabetes Numerous mechanisms contribute to the pathogenesis of diabetic vascular diseases, many of which are complex, incompletely understood and continue to be intensely investigated. The hallmark of diabetic vascular disease is thickening of the basement membranes, which develop in relation to the duration of diabetes and degree of glycemic control. 6 The contribution of hyperglycemia, hyperinsulemia and dyslipidemia to diabetic vascular complications will be briefly reviewed. Hyperglycemia. Although still controversial, hyperglycemia has emerged as a leading candidate responsible for the excess of diabetes risk. 5 A number of studies following type 1 and type 2 diabetic individuals, adjusting for other risks, have substantiated a dose response
2 2 relationship between hyperglycemia and CVD risk. In the San Antonio Heart Study, diabetic subjects in the top of the quartile of fasting plasma glucose (FPG) had a CVD mortality 4.7 times the risk of subjects in quartiles 1 and 2 combined. 7 Ten years of follow-up of type 1 diabetics in the Wisconsin Epidemiological Study, showed that for every 1 percent increase in glycated hemoglobin, the risk ratio for CVD nearly doubled. 8 A continuous graded relationship between blood glucose and risk of CVD is demonstrated in the preliminary data from the 2853 patients in the Framingham Offspring Study. 9 It is unclear if there is a critical value that exists above which CVD raises. Although better glycemic control is broadly beneficial, these are observational studies only, and to date, there is little evidence that treating to tighter glycemic levels reduces CVD risk. A number of mechanisms have been proposed for the contribution of hyperglycemia in CVD. Suggested mechanisms include: glycation of collagen and other vessel-wall proteins and lipoproteins; accelerated generation of reactive oxygen species; increased oxidative stress on glycated end products, LDL cholesterol, and vascular endothelial cells; alteration in haemorrheological characteristics or changes in vascular reactivity. 2 Extracellular glucose can glycate proteins without enzyme action and generate oxidative by-products. Glycated proteins (Advanced Glycation End-products) accumulate in the extracellular matrix and bind to specific AGE-receptors that are expressed on the cell surface. AGE receptors are being extensively investigated for their contribution to the accelerated vascular complications of diabetes. Cells contain several receptors of AGEs that mediate their biological effects. Exposure to AGE modified proteins can elicit the production of inflammatory cytokines from vascular cells, cause impaired endothelial dependent vasodilator function and increase the expression of various leukocyte adhesion molecules implicated in atherosclerosis. 5 Insulin. Although it has been suggested that hyperinsulinemia may be the link between hyperglycemia and CVD, the specific role of insulin in the etiology of atherosclerosis is poorly understood. It is thought that insulin resistance and compensatory hyperinsulinemia may contribute to atherogenic risk through several different mechanisms. Insulin resistance commonly precedes hyperglycemia, and insulin resistance has been shown to have a positive correlation with CVD. Diabetes is frequently associated with the risk factors of obesity, dyslipidemia, and hypertension. Most individuals with this group of disorders also have insulin resistance. This group of disorders has been named syndrome X, the insulin resistance syndrome, and CVD metabolic syndrome. Insulin resistance syndrome includes glucose intolerance, and elevated levels of fasting insulin and triglycerides. 10 In normal conditions, insulin has a protective vasodilatory action that may be mediated by nitric oxide. Nitric oxide has documented anti-atherogenic functions via the suppression of adhesion molecule expression and inhibition of smooth-muscle-cell migration and growth. In insulin resistance states, the ability of insulin to induce vasodilation is low, suggesting an impairment or inactivation of nitric oxide. Increased
3 3 insulin action is also thought to contribute to atherogenesis through smooth-muscle cell hypertrophy and hyperplasia and increased extracellular proteins. A hypothesis generated to explain data from the Framingham Offspring Study, suggested that the atherogenic effects of hyperglycemia or hyperinsulinemia might be mediated through factors predisposing to acute thrombosis. 10 Markers of decreased fibrinolytic potential include elevated levels of plasminogen activator inhibitor 1 (PAI-1) antigen or tissue-type plasminogen activator (tpa) antigen. These markers are associated with increased risk for CVD among non-diabetic individuals. The Framingham Offspring Study, found strong positive associations between levels of fasting insulin and levels of markers indicating impaired fibrinolyisis in both men and women. 10 Elevated levels of PAI-1 appear to increase the formation of acellular, thin-walled plaques susceptible to rupture. Increases of fibrinolytic markers have been shown to correlate with elevated markers of inflammation and endothelial dysfunction. 10 Is fibrinolysis the cause or the effect of hyperinsulinemia is a question that remains unanswered. Final comments from the Framingham Offspring Study suggest that modification of the fibrinolytic state by improving insulin sensitivity, particularly in people with impaired or diabetic glucose tolerance, may offer a new approach to reducing CVD risk. Dyslipidemia and Associated Metabolic Abnormalities. Dysplipidemia is the most thoroughly studied and established mechanism for the increased risk of atherogenesis identified in type II diabetes. 5 Studies investigating dyslipidemia and diabetes have been done primarily with individuals with type II diabetes because of the increased incidence of dyslipidemia in this population. 11 In type l patients with good glycemic control, lipids may appear to be better than the average for subjects without diabetes, however lipoproteins may be abnormal in composition and as a result more atherogenic. 12 Numerous studies have also shown that dyslipidemias are more prevalent in diabetic women, and probably a very important contributor to the increased CVD risk in this group. The most common dyslipidemias observed in type II diabetes are high triglycerides and reduced high-density lipoprotein (HDL) cholesterol. Low-density lipoprotein concentration is not usually higher than in individuals without diabetes, but the LDL particles themselves tend to be small and dense. Small dense LDL particles are believed to be more atherogenic because they are more easily glycated and susceptible to oxidation. 11 Interventional studies have shown that the benefit of lowering LDL is similar in the diabetic and non-diabetic population. 11 Central to the pathogenesis of dyslipidemia in diabetes is the increased presentation of free fatty acids to the liver, which provide the substrate for triglyceride-rich lipoproteins - very low density (VLDL) production in the liver. 5 Abdominal obesity, a common finding in type II diabetic men, provides a further source of free fatty acids which in turn fuel production of VLDL. Contributing to the adverse effect of increased VLDL production is the decreased catabolism of triglyceride-rich lipoproteins. Liprotein lipase, an enzyme
4 4 that plays a central role in clearing postprandial lipemia (consisting largely of triglyceride-rich particles), is decreased in uncontrolled type ll diabetes. 5 Contiguously, states of higher VLDL are associated with low HDL levels because of the intimate relationship between lipoprotein lipase activity (reduced in DM), cholesterol ester transfer protein activity, and efficient HDL. The protective role of HDL in shielding LDL from oxidation also appears to be diminished in diabetes, suggesting differences in the qualitative as well as quantitative aspects of HDL in diabetes. 5 Conclusion Knowledge of diabetes and the mechanisms that predispose its sufferers to accelerated atherosclerosis has advanced. AGE receptors and metabolic syndrome have become part of our new language. We need to prepare ourselves to deal with the accelerating challenge of both diabetes and cardiovascular disease. Cardiac rehabilitation or other secondary prevention programs provide expert and quantifiable gains with respect to the identification and modification of risk factors which lead to the development and progression of atherosclerosis and its all too often intimate companion, diabetes (Stone, Cyr, Friesen, Kennedy-Symmonds, Stene, 1999). 13 References 1. Gaziano, J. M. (2001). Global burden of cardiovascular disease. In Braunwald E, Zipes D.P., & Libby P. (Eds.), Heart disease a textbook of cardiovascular medicine (pp. 1-17). Philadelphia: W.B. Saunders. 2. Nathan, M. N. & Singer, D. E. (1997). The epidemiology of cardiovascular disease in type 2 diabetes mellitus: How sweet it is... or is it? Lancet, 350 (suppl 1), Stamler, J., Vaccaro, O., Neaton, J., Wentworth d. for the Multiple Risk Factor Intervention Trial Research group. (1993). Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16, Turner, R. C. (1998). The U.K. Prospective Diabetes Study: A review. Diabetes Care, 21 (Suppl 3), C35-C Nesto, R. W. & Libby, P. (2001). Diabetes Mellitus and the Cardiovascular System. In Braunwald E, Zipes D.P., & Libby P. (Eds.), Heart Disease A textbook of cardiovascular medicine (6 ed., pp ). Philadelphia: S.B. Saunders. 6. Feener, E. P., & King, G. L. (1997). Vascular dysfunction in diabetes mellitus. Lancet, 350 (Suppl), Wei, M., Haffner, S. M., & Gaskill, S. P. (1998). Effects of diabetes and level of ischemia on allcause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care, 21, Klein, R., Klein, B. E., & Moss, S. E. (1995). The Wisconsin epidemiological study of diabetic retinopathy. Diabetes, 44, Kannel W.B., & McGee, D. L. (1979). Diabetes and cardiovascular disease. The Framingham study. Journal of the American Medical Association, 2411,
5 5 10. Meigs, J. B., Mittleman, M. A., Nathan, D. M., Tofler, G. H., Singer, D. E., Murphy-Sheey, P. M., Lipinska, I., & Wilson, P. W. F. (2000). Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham offspring study. Journal of the American Medical Association, 283, Powers, A. C. (2001). Diabetes Mellitus. In Braunwald E, Fauci Anthony, Kasper D, Hauser S, Longo D, & Jameson JL (Eds.), Harrison's principles of internal medicine (15 ed., pp ). New York: McGraw-Hill Companies. 12. Adults with diabetes and patients with concomitant dyslipidemia and hypertension (1999). In A.Gotto, & H. Pownall (Eds.), Manuel of lipid disorders: Reducing the risk for coronary heart disease (2 ed., pp ). Media: Williams & Wilkins. 13. Stone, J. A., Cyr, C., Friesen, M., Kennedy-Symmonds, H., & Stene, R. (1999). Canadian Guidelines for Cardiac Rehabilitation and Cardiovascular Disease Prevention. In J.A.Stone, C. Cyr, M. Friesen, H. Kennedy-Symmonds, & R. Stene (Eds.), (1 ed., pp. 1-25). Winnipeg. Acknowledgements Editing suggestions were kindly provided by Dr. Alun Edwards, MB, F.R.C.P. Clinical Associate Professor Department of Medicine, University of Calgary Medical Leader, Regional Diabetes Education Centre, Calgary Health Region, Calgary Alberta and Dr. Karen L Then, MN, Phd, NPC, Associate Professor, Faculty of Nursing, University of Calgary, Calgary Alberta.
6 6 Copyright 2003 Canadian Association of Cardiac Rehabilitation. All rights reserved For more information please contact: the Association Manager CACR, 1390 Taylor Avenue Winnipeg, MB R3M 3V8
Arteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.193 Lipid Profile as Early Predictor of Complication
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationRole of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationAnnals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationFrequency of Dyslipidemia and IHD in IGT Patients
Frequency of Dyslipidemia and IHD in IGT Patients *Islam MS, 1 Hossain MZ, 2 Talukder SK, 3 Elahi MM, 4 Mondal RN 5 Impaired glucose tolerance (IGT) is often associated with macrovascular complications.
More informationMetabolic control and serum lipid changes in diabetic Iraqi men
www.muthjm.com Muthanna Medical Journal 2017; 4(2):56-61 Metabolic control and serum lipid changes in diabetic Iraqi men Aqeel Raheem Hassan 1* Abstract The objective of this study is to demonstrate the
More informationHyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes
...PRESENTATIONS... Hyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Based on a presentation by Ronald B. Goldberg, MD Presentation Summary Atherosclerosis accounts for approximately
More informationDiabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center
Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationTracking a Killer Molecule
Tracking a Killer Molecule Mercodia Oxidized LDL ELISA www.mercodia.com Mercodia Oxidized LDL ELISA products Product Catalog No Kit size Oxidized LDL ELISA 10-1143-01 96 wells Oxidized LDL competitive
More informationNormal blood vessels A= artery V= vein
Normal blood vessels A= artery V= vein Artery (A) versus vein (V) ARTERIOSCLEROSIS Arteriosclerosis ="hardening of the arteries" arterial wall thickening and loss of elasticity. Three patterns are recognized,
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationMetabolic Syndrome.
www.bmiweightloss.com.au What is the metabolic syndrome? The was first described in 1988 by Gerald Reavson It was originally described as the clustering of four conditions These conditions when present
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationMetabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationKEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers
CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes
More informationPart 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD
Week 3: Cardiovascular Disease Learning Outcomes: 1. Define the difference forms of CVD 2. Describe the various risk factors of CVD 3. Describe atherosclerosis and its stages 4. Describe the role of oxidation,
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationMULTIFACTORIAL ANALYSIS OF CARDIOVASCULAR RISK FACTORS IN A GROUP OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
2014 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 21(4):327-333 doi: 10.2478/rjdnmd-2014-0040 MULTIFACTORIAL ANALYSIS OF CARDIOVASCULAR RISK FACTORS
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationInvited Review. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases
Histol Histopathol (2000) 15: 557-571 Histology and Histopathology Cellular and Molecular Biology Invited Review Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular
More informationAlthough medical advances have curbed
PREVENTION OF CORONARY HEART DISEASE IN THE METABOLIC SYNDROME AND DIABETES MELLITUS * Sherita Hill Golden, MD, MHS ABSTRACT The leading cause of death in patients with diabetes is cardiovascular disease.
More informationTHE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES
Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationImpact of Chronicity on Lipid Profile of Type 2 Diabetics
Impact of Chronicity on Lipid Profile of Type 2 Diabetics Singh 1, Gurdeep & Kumar 2, Ashok 1 Ph.D. Research Scholar, Department of Sports Science, Punjabi University Patiala, India, Email: drgurdeep_sahni@yahoo.co.in
More informationDECLARATION OF CONFLICT OF INTEREST. None
DECLARATION OF CONFLICT OF INTEREST None BURDEN OF CORONARY ARTERY DISEASE IN DIABETES IN INDIA Amal Kumar Banerjee MD, DM,FACC,FESC,FACP,FAPSC,FICC President Association of Physicians of India SAARC Cardiac
More informationLecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors
Lecture 8 Cardiovascular Health 1 Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors 1 Human Health: What s Killing Us? Health in America Health is the U.S Average life
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationA Study to Show Postprandial Hypertriglyceridemia as a Risk Factor for Macrovascular Complications in Type 2 Diabetis Mellitus
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/21 A Study to Show Postprandial Hypertriglyceridemia as a Risk Factor for Macrovascular Complications in Bingi Srinivas
More informationDiabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions
Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions Diabetes is one of the largest global health emergencies of 21 st century, with the number of people with
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationPEOPLE WITH TYPE 2 diabetes are disproportionately
0163-769X/04/$20.00/0 Endocrine Reviews 25(1):153 175 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/er.2002-0034 Nontraditional Risk Factors for Cardiovascular Disease in Diabetes
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More information... REPORT... The Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease: Understanding the Role of Insulin Resistance
... REPORT... The Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease: Understanding the Role of Insulin Resistance David M. Kendall, MD; Anne Peters Harmel, MD Abstract The most common and
More informationPathophysiology of Cardiovascular System. Dr. Hemn Hassan Othman, PhD
Pathophysiology of Cardiovascular System Dr. Hemn Hassan Othman, PhD hemn.othman@univsul.edu.iq What is the circulatory system? The circulatory system carries blood and dissolved substances to and from
More informationEicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different?
Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different? Trevor A Mori, Ph.D., Professor, School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth,
More informationGlossary For TheFatNurse s For All Ages Series Apolipoprotein B (APOB or ApoB) are the primary apolipoproteins of chylomicrons and low-density lipoproteins (LDL - known commonly by the misnomer "bad cholesterol"
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More information3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.
U.S. Adults: 1988 Nineteen states with 10-14% 14% Prevalence of Obesity (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Metabolic John P. Cello, MD Professor of Medicine and Surgery, University of California,
More informationChapter (5) Etiology of Low HDL- Cholesterol
Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the
More informationFOCUS ON CARDIOVASCULAR DISEASE
The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.
More informationPREDIABETES TESTING SERVICES
PREDIABETES TESTING SERVICES ASSESSING DIABETES RISK IN ASYMPTOMATIC ADULTS Depending upon population characteristics, up to 70% of individuals with prediabetes will ultimately progress to diabetes at
More informationHBA1C: PREDICTOR OF DYSLIPIDEMIA AND ATHEROGENICITY IN DIABETES MELLITUS
Original Article HBA1C: PREDICTOR OF DYSLIPIDEMIA AND ATHEROGENICITY IN DIABETES MELLITUS Chintamani Bodhe*, Deepali Jankar**, Tara Bhutada***, Milind Patwardhan****, Mrs Varsha Patwardhan***** ABSTRACT
More informationLipid/Lipoprotein Structure and Metabolism (Overview)
Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationDyslipidaemia pattern amongst diabetic patients visiting a tertiary care hospital in Eastern Odisha
International Journal of Advances in Medicine Behera SN et al. Int J Adv Med. 217 Dec;4(6):1662-1667 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/1.1823/2349-3933.ijam2175186
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationAdvanced Concepts of Personal Training Study Guide Answer Key
Advanced Concepts of Personal Training Study Guide Answer Key Lesson 22 Working with Special Populations LESSON TWENTY TWO Lesson Twenty Two Working with Special Populations WORKING WITH SPECIAL POPULATIONS
More informationATHEROSCLEROSIS زيد ثامر جابر. Zaid. Th. Jaber
ATHEROSCLEROSIS زيد ثامر جابر Zaid. Th. Jaber Objectives 1- Review the normal histological features of blood vessels walls. 2-define the atherosclerosis. 3- display the risk factors of atherosclerosis.
More informationDiabetes and Heart Disease
Diabetes and Heart Disease Sarah Alexander, MD Assistant Professor of Medicine Division of Cardiology Rush University Medical Center 2/8/2017 Rush is a not-for-profit health care, education and research
More informationhttp://noodlemaz.wordpress.com/category/science/cancer/ Outline Introduction Serious nature of Cardiovascular Disease (CVD) How to prevent CVD? The disease process Damage and plaque development Current
More informationIndex. Note: Page numbers of article titles are in boldface type.
Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced
More informationDiabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?
Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double
More informationEFFECT OF GOOD GLYCEMIC CONTROL ON LIPID PROFILE IN TYPE 2 DIABETES MELLITUS PATIENTS IN AL HUSSEIN TEACHING HOSPITAL
Thi-Qar Medical Journal (TQMJ): Vol(5) No(2):2011(39-44) EFFECT OF GOOD GLYCEMIC CONTROL ON LIPID PROFILE IN TYPE 2 DIABETES MELLITUS PATIENTS IN AL HUSSEIN TEACHING HOSPITAL Dr. Akeel bal-yaqobi *, Dr.
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationDysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale
Dysglycaemia and Hypertension Dr E M Manuthu Physician Kitale None Disclosures DM is MI equivalent MR FIT Objective was to assess predictors of CVD mortality among men with and without diabetes and
More informationCardiovascular disease and diabetes Vascular harmony
Cardiovascular disease and diabetes 2018 Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics
More informationCardiovascular Disease Risk Factors:
Cardiovascular Disease Risk Factors: Risk factors are traits or habits that increase a person's chances of having cardiovascular disease. Some risk factors can be changed. These risk factors are high blood
More informationClinical profile, risk factors and outcome of ischemic heart disease patients at tertiary care centre
International Journal of Advances in Medicine http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20183434 Clinical profile,
More informationBerries and Cardiovascular Health
Berries and Cardiovascular Health Britt Burton-Freeman, PhD Institute for Food Safety and Health Illinois Institute of Technology bburton@iit.edu Berry Health Benefits Symposium Westlake Village CA, 2011
More informationWatermark. Interaction between Neuropathy and PAD
Interaction between Neuropathy and PAD Javier La Fontaine, DPM, MS Associate Professor Department of Plastic Surgery UT Southwestern Medical Center Dallas, Texas Objectives Understand vascular disease
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More information13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:
CARDIOVASCULAR DISEASES (CVD) and NUTRITION Major cause of morbidity & mortality in Canada & other developed countries e.g., majority of approved health claims on food labels relate to lowering CVD Relation
More informationAtherogenic Index as a Predictor of Cardiovascular Risk among Women with Different Grades of Obesity
1767 Atherogenic Index as a Predictor of Cardiovascular Risk among Women with Different Grades of Obesity Pallavi S. Kanthe 1*, Bheemshetty S. Patil 2, Shrilaxmi Bagali 3, Anita Deshpande 4, Gouhar Banu
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationREAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING
REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationPERIPHERAL ARTERIAL DISEASE: INCIDENCE, RISK FACTORS, AND DIAGNOSIS. Andrew Althouse. B.S., Carnegie Mellon University, 2008
PERIPHERAL ARTERIAL DISEASE: INCIDENCE, RISK FACTORS, AND DIAGNOSIS by Andrew Althouse B.S., Carnegie Mellon University, 2008 M.A., University of Pittsburgh, 2010 Submitted to the Graduate Faculty of the
More informationPathology of Coronary Artery Disease
Pathology of Coronary Artery Disease Seth J. Kligerman, MD Pathology of Coronary Artery Disease Seth Kligerman, MD Assistant Professor Medical Director of MRI University of Maryland Department of Radiology
More informationAssessment of clinical profile of coronary artery disease in Indian Population
Original article: Assessment of clinical profile of coronary artery disease in Indian Population 1Dr J S Dhadwad, 2 Dr N G Karandikar 1 Assistant Professor, Department of Medicine, P. Dr. D Y Patil Medical
More information10/8/2018. Lecture 9. Cardiovascular Health. Lecture Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor
Lecture 9 Cardiovascular Health 1 Lecture 9 1. Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor 1 The Heart Muscular Pump The Heart Receives blood low pressure then increases the pressure
More informationAsubstantial minority of adults and adolescents
THE METABOLIC SYNDROME AS A RISK FACTOR FOR TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE Roger S. Blumenthal, MD* ABSTRACT This paper discusses the prevalence and clinical significance of the metabolic syndrome
More informationARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk
ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk CONSIDER YOUR HEART HEALTH: REDUCE YOUR CHOLESTEROL Uncontrolled or continuous high cholesterol
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More information2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP
Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox Carl J. Lavie, MD, FACC, FACP, FCCP Professor of Medicine Medical Director, Cardiac Rehabilitation and Preventive Cardiology
More informationLipid profile in Diabetes Mellitus
International Journal of Biotechnology and Biochemistry ISSN 0973-2691 Volume 13, Number 2 (2017) pp. 123-131 Research India Publications http://www.ripublication.com Lipid profile in Diabetes Mellitus
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationEpidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl
Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk Eberhard Standl European Heart House Sophia Antipolis Thursday, June 17, 2010 IDF Diabetes Atlas 2009: Global Numbers Still
More information